Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
23 Dezembro 2024 - 10:17PM
Edgar (US Regulatory)
Exhibit 99
The name and present principal occupation of each of
the executive officers and directors of Gilead Sciences, Inc. are set forth below. Unless otherwise noted, each of these persons have
as their business address c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404.
Name |
Title |
Citizenship |
Principal Occupation and, if not employed by Gilead Sciences, Inc., Name, Principal Business and
Address of Employer |
Daniel P. O’Day |
Chief Executive Officer, Chairman and Director |
United States |
* |
Jacqueline K. Barton, Ph.D. |
Director |
United States |
Professor Emerita, California Institute of Technology |
Jeffrey A. Bluestone, Ph.D. |
Director |
United States |
President and Chief Executive Officer, Sonoma Biotherapeutics |
Sandra J. Horning, M.D. |
Director |
United States |
Retired Chief Medical Officer, Roche Inc. |
Kelly A. Kramer |
Director |
United States |
Retired Executive Vice President and Chief Financial Officer, Cisco Systems, Inc. |
Ted W. Love,
M.D. |
Director |
United States |
Chair of Board of Directors, Biotechnology Innovation Organization |
Harish Manwani |
Director |
Singapore |
Senior Operating Partner, Blackstone |
Javier J. Rodriguez |
Director |
Mexico |
Chief Executive Officer, DaVita, Inc. |
Anthony Welters |
Director |
United States |
Chairman and Chief Executive Officer, CINQ Care |
Andrew D. Dickinson |
Chief Financial Officer |
United States |
* |
Johanna Mercier |
Chief Commercial Officer |
United States |
* |
Merdad V. Parsey, M.D., Ph.D. |
Chief Medical Officer |
United States |
* |
Deborah H. Telman |
Executive Vice President, Corporate Affairs and General Counsel |
United States |
* |
* The present principal occupation for each of these individuals is officer
of Gilead Sciences, Inc. and officer, trustee and/or director of other affiliated entities.
Gilead Sciences (NASDAQ:GILD)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Gilead Sciences (NASDAQ:GILD)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024